Clinical Trial Update: SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of camrelizumab (SHR-1210) and apatinib in extensive-disease small-cell lung cancer after failure of first-line therapy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Small-cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-08-07